Jianan Hui

1.1k total citations · 1 hit paper
24 papers, 431 citations indexed

About

Jianan Hui is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jianan Hui has authored 24 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Genetics and 6 papers in Molecular Biology. Recurrent topics in Jianan Hui's work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Jianan Hui is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Jianan Hui collaborates with scholars based in China, United States and Germany. Jianan Hui's co-authors include Michael Heuser, Jianxiang Wang, Su‐Peng Yeh, Andre C. Schuh, Diego A. Gianolio, Pau Montesinos, Stéphane de Botton, Hartmut Döhner, Rodrigo T. Calado and Christian Récher and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Jianan Hui

21 papers receiving 424 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Jianan Hui

Since Specialization

Citations

This map shows the geographic impact of Jianan Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianan Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianan Hui more than expected).

Fields of papers citing papers by Jianan Hui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianan Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianan Hui. The network helps show where Jianan Hui may publish in the future.

Co-authorship network of co-authors of Jianan Hui

This figure shows the co-authorship network connecting the top 25 collaborators of Jianan Hui. A scholar is included among the top collaborators of Jianan Hui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianan Hui. Jianan Hui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Integrated Microfluidic System for One-Stop Multiplexed Exosomal PD-L1 and MMP9 Automated Analysis with Deep Learning Model YOLO 2025 ·Micromachines ·(unknown), Wenjing Zhang, Qiang Shi, Jianan Hui, Jieyu Wang, Yuxin Song, Shuangming Yang	0
2	A deep learning-based integrated analytical system for tumor exosome on-chip isolation and automated image identification 2025 ·Talanta Open ·(unknown), (unknown), (unknown), Jianan Hui, (unknown), Hongju Mao, Qiang Shi, Shuangming Yang	3
3	AuNP/Magnetic Bead-Enhanced Electrochemical Sensor Toward Dual Saliva Alzheimer’s Biomarkers Detection 2025 ·Sensors ·(unknown), Jieyu Wang, Hongju Mao, Lin Zhou, Zhenhua Wu, (unknown), Teng Sun, Jianan Hui, Guowu Ma	2
4	Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1 -mutated AML 2025 ·Blood Advances ·Pau Montesinos, Dylan M. Marchione, Christian Récher, Michael Heuser, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Rodrigo T. Calado, Andre C. Schuh, Su-Peng Yeh, Adriana E. Tron, Jianan Hui, Diego A. Gianolio, Sung Choe, Prapti A. Patel, Stéphane de Botton, Courtney D. DiNardo, Hartmut Döhner	3
5	P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE 2023 ·HemaSphere ·Hartmut Döhner, Pau Montesinos, (unknown), Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Diego A. Gianolio, Prapti A. Patel, Christian Récher, Stéphane de Botton	0
6	An exploration of National Weather Service daily forecasts using R Shiny 2023 ·Computational Statistics ·(unknown), (unknown), Jianan Hui, (unknown)	1
7	Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine 2023 ·Blood ·Courtney D. DiNardo, Dylan M. Marchione, Michael Heuser, Jianan Hui, Diego A. Gianolio, Scott R. Daigle, Sung Choe, Prapti A. Patel, Stéphane de Botton, Hartmut Döhner	1
8	Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. 2023 ·Journal of Clinical Oncology ·Stéphane de Botton, Pau Montesinos, (unknown), Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Diego A. Gianolio, Prapti A. Patel, Christian Récher, Hartmut Döhner	12
9	Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study 2022 ·Blood ·Hartmut Döhner, Dylan M. Marchione, Sung Choe, Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, (unknown), Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Adolfo de la Fuente, Jianan Hui, (unknown), Diego A. Gianolio, Scott R. Daigle, Courtney D. DiNardo, Stéphane de Botton	3
10	Analyzing Human Periodontal Soft Tissue Inflammation and Drug Responses In Vitro Using Epithelium-Capillary Interface On-a-Chip 2022 ·Biosensors ·(unknown), Ni Kou, Fan An, Zehang Gao, Tian Tian, Jianan Hui, Chen Chen, Guowu Ma, Hongju Mao, Huiying Liu	26
11	Microfluidic Organ-on-a-Chip System for Disease Modeling and Drug Development 2022 ·Biosensors ·(unknown), Jianan Hui, P. Yang, Hongju Mao	56
12	Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. 2022 ·Journal of Clinical Oncology ·Stéphane de Botton, Sung Choe, Dylan M. Marchione, Pau Montesinos, Christian Récher, (unknown), (unknown), Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Shuchi S. Pandya, Diego A. Gianolio, Scott R. Daigle, Courtney D. DiNardo, Hartmut Döhner	1
13	Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia breakdown → 2022 ·New England Journal of Medicine ·Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Scott R. Daigle, Jianan Hui, Shuchi S. Pandya, Diego A. Gianolio, Stéphane de Botton, Hartmut Döhner	295
14	AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation 2021 ·Blood ·Pau Montesinos, Christian Récher, Susana Vives, Ewa Zarzycka, Jianxiang Wang, Giambattista Bertani, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Scott R. Daigle, Jianan Hui, Vickie Zhang, Shuchi S. Pandya, Diego A. Gianolio, Stéphane de Botton, Hartmut Döhner	7
15	Multi-Stage Microfluidic Capture Arrays for Detecting Various Alzheimer's Disease Biomarkers in Saliva 2021 ·Pengcheng Zhao, Jianan Hui, Hongju Mao, Guowu Ma, Huiying Liu	1
16	Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers 2020 ·British Journal of Clinical Pharmacology ·Tobias Litzenburger, Jürgen Steffgen, (unknown), Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Christian Harcken, (unknown), Jing Wu, Sabrina Wiebe, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, (unknown), Jianan Hui	4
17	Geometric ergodicity of a more efficient conditional Metropolis-Hastings algorithm 2020 ·Communication in Statistics- Theory and Methods ·Jianan Hui, James M. Flegal, (unknown)	0
18	Empirical profile Bayesian estimation for extrapolation of historical adult data to pediatric drug development 2020 ·Pharmaceutical Statistics ·(unknown), Jianan Hui, Qiqi Deng	2
19	32 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a covalent inhibitor of brutons tyrosine kinase in phase 1 clinical trials in healthy volunteers 2019 ·Abstracts ·Tobias Litzenburger, Fabian Müller, Armin Schultz, Elliott Klein, Meera Ramanujam, Jing Wu, Sabrina Wiebe, (unknown), Jianan Hui, Xiujiang Li, Mary Flack, Steven J. Padula, Sudha Visvanathan, Jürgen Steffgen, (unknown)	1
20	A machine learning approach to galaxy–LSS classification – I. Imprints on halo merger trees 2017 ·Monthly Notices of the Royal Astronomical Society ·Jianan Hui, (unknown), Xinping Cui, James M. Flegal	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact